Abstract:Unlike normal cells, cancer cells frequently exhibit supernumerary centrosomes, leading to formation of multipolar spindles that can trigger cell death. Nevertheless, cancer cells with supernumerary centrosomes escape the deadly consequences of unequal segregation of genomic material by coalescing their centrosomes into two poles. This unique trait of cancer cells presents a promising target for cancer therapy, focusing on selectively attacking cells with supernumerary centrosomes. Nek2A is a kinase involved in mitotic regulation, including the centrosome cycle, where it phosphorylates linker proteins to separate centrosomes. In this study, we investigated if Nek2A also prevents clustering of supernumerary centrosomes, akin to its separation function. Reduction of Nek2A activity, achieved through knockout, silencing, or inhibition, promotes centrosome clustering, whereas its overexpression results in inhibition of clustering. Significantly, prevention of centrosome clustering induces cell death, but only in cancer cells with supernumerary centrosomes, both in vitro and in vivo. Notably, none of the known centrosomal (e.g., CNAP1, Rootletin, Gas2L1) or non-centrosomal (e.g., TRF1, HEC1) Nek2A targets were implicated in this machinery. Additionally, Nek2A operated via a pathway distinct from other proteins involved in centrosome clustering mechanisms, like HSET and NuMA. Through TurboID proximity labeling analysis, we identified novel proteins associated with the centrosome or microtubules, expanding the known interaction partners of Nek2A. KIF2C, in particular, emerged as a novel interactor, confirmed through coimmunoprecipitation and localization analysis. The silencing of KIF2C diminished the impact of Nek2A on centrosome clustering and rescued cell viability. Additionally, elevated Nek2A levels were indicative of better patient outcomes, specifically in those predicted to have excess centrosomes. Therefore, while Nek2A is a proposed target, its use must be specifically adapted to the broader cellular context, especially considering centrosome amplification. Discovering partners such as KIF2C offers fresh insights into cancer biology and new possibilities for targeted treatment.

Regulation of Nek Kinase Family to Centrosome and Its Correlation with Tumorigenesis

The NEK family of serine/threonine kinases as a biomarker for cancer

Role of NEK2 in tumorigenesis and tumor progression

Targeting NEK2 as a promising therapeutic approach for cancer treatment

Nek4 Regulates Entry into Replicative Senescence and the Response to DNA Damage in Human Fibroblasts.

NEK Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types

Nek2A kinase regulates the localization of numatrin to centrosome in mitosis.

Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction

Overexpression of NIMA-related Kinase 6 (NEK6) Contributes to Malignant Growth and Dismal Prognosis in Human Breast Cancer.

The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells

Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis

Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells

The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability

Structure, function, and evolution of plant NIMA-related kinases: implication for phosphorylation-dependent microtubule regulation

Frequent Nek1 Overexpression in Human Gliomas.

A Nima-Related Kinase, Cnk4, Regulates Ciliary Stability And Length

The role of mitotic kinases in coupling the centrosome cycle with the assembly of the mitotic spindle.

Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer

The role of centrosomal Nlp in the control of mitotic progression and tumourigenesis

Nek2A specifies the centrosomal localization of Erk2.

NEK7 promotes gastric cancer progression as a cell proliferation regulator